Data Supplement
- Supplemental Data -
Supplementary Figure 1 - Box and Whisker plots of model estimates of Emax for mRNA(A) or activity (B) following treatment of human hepatocytes with omeprazole, phenobarbital, efavirenz, or rifampicin for 6, 12, 24, 48, or 72 hr.
Supplementary Figure 2 - Box and Whisker plots of model estimates of EC50 for mRNA(A) or activity (B) following treatment of human hepatocytes with omeprazole, phenobarbital, efavirenz, or rifampicin for 6, 12, 24, 48, or 72 hr.
Supplementary Figure 3 - Overall average %CV (for triplicate fold induction, across all donors) for each prototypical inducer at each time point, for mRNA and activity. Dotted line illustrates 30% CV.
Supplementary Figure 4 - Comparison of the absolute average fold error (AAFE) between the best model estimates (determined using the model with the lowest AICc) for Emax (A) or EC50 (B) and each respective model fit, for all CYP inducers and isoforms.
Supplementary Table 1 - Donor demographics for human hepatocyte donors.
Supplementary Table 2 - Inducer Test Concentrations.